Objective: Joint hypermobility, common in childhood, can be associated with severe pain and significant morbidity. Physiotherapy, the mainstay of treatment, lacks a robust evidence base. This study is aimed at determining the best physiotherapy intervention in managing childhood hypermobility.
Methods: A prospective randomized comparative trial (RCT) compared a 6-week generalized programme, improving muscular strength and fitness, with a targeted programme aimed at correcting motion control of symptomatic joints. Patients were assessed on symptom scores (pain/global-impact), function, muscle strength and fitness.
Results: Fifty-seven children, aged 7-16 years with symptomatic hypermobility, were randomly assign to receive a targeted (T; n = 30) or generalized (G; n = 27) programme. Statistically significant improvements were demonstrated in both the children's and parental pain scores across both the randomized groups between baseline and follow-up assessments (P < 0.05). However, the difference in improvement between the groups was not statistically significant. Child's assessment of change in pain score: mean difference (95% CI) T - G, 3.97 (-15.59, 20.85) at the end of treatment and 9.41 at 3-month follow-up (-17.42, 36.24). At the end of treatment, parental assessment of change in pain score, T - G was: -0.27 (-15.05, 14.50) and at 3-month follow-up it was: -9.48 (-26.40, 7.43). Change in parental global assessment was statistically significant, in favour of targeted physiotherapy at final assessment: -21.29 (-40.03, -2.55).
Conclusion: This is the first physiotherapy RCT for treating hypermobility. It demonstrated significant and sustained reduction in pain when both groups were combined, but did not detect any difference between the groups. This study provides normative and methodological data for future studies of hypermobility.
Trial Registration: Current Controlled Trials, www.controlled-trials.com, ISRCTN58523390.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/rheumatology/kep362 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring.
JAMA Netw Open
January 2025
Davidoff Cancer Center, Rabin Medical Center, Petach Tikvah, Israel.
Importance: Three similar phase 3 randomized clinical trials have investigated PD-1/PD-L1 (programmed cell death 1 protein/programmed cell death 1 ligand 1) inhibitors in combination with platinum-based chemotherapy vs chemotherapy alone as first-line treatment for advanced urothelial carcinoma (IMvigor130, atezolizumab; KEYNOTE-361, pembrolizumab; and CheckMate901, nivolumab). Only CheckMate901 reported overall survival (OS) benefit for the combination. The reason for these inconsistent results is unclear.
View Article and Find Full Text PDFCombination of Baricitinib and Phototherapy in Adults With Active Vitiligo: A Randomized Clinical Trial.
JAMA Dermatol
January 2025
CNRS, Immuno ConcEpT, UMR 5164, University Bordeaux, Bordeaux, France.
Importance: Vitiligo is a chronic autoimmune disorder leading to skin depigmentation and reduced quality of life (QOL). Patients with extensive and very active disease are the most difficult to treat.
Objective: To assess the efficacy and adverse events of baricitinib combined with narrowband UV-B in adults with severe, active, nonsegmental vitiligo.
The aim of the study is to apply mathematical methods to generate forecasts of the dynamics of random values of the percentage increase in the total number of infected people and the percentage increase in the total number of recovered and deceased patients. The obtained forecasts are used for retrospective forecasting of COVID-19 epidemic process dynamics in St. Petersburg and in Moscow.
View Article and Find Full Text PDFCapillary refill time paradoxically decreases in a blood loss shock model.
Intensive Care Med Exp
January 2025
Department of Emergency Medicine in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, 582 25, Linköping, Sweden.
Background: This study aimed to investigate whether changes in capillary refill (CR) time precede macrovascular signs of deterioration in a human model of blood loss shock. The study was conducted at the Department of Emergency Medicine in Linköping, Sweden, and involved 42 healthy volunteers aged 18-45. Participants were randomized into two provocations of applied lower body negative pressure (LBNP): a stepwise escalation protocol and a direct application protocol, to simulate gradual and acute blood loss.
View Article and Find Full Text PDFEfficacy of Ceftazidime-avibactam in treating Gram-negative infections: a systematic review and meta-analysis.
Eur J Clin Microbiol Infect Dis
January 2025
University of Sassari, Sassari, Italy.
Introduction: Ceftazidime-avibactam (CAZ-AVI) has emerged as a promising treatment option for Gram-negative infections, particularly those caused by CAZ-Non-Susceptible (NS) pathogens. This systematic review and meta-analysis aim to assess the efficacy and safety of CAZ-AVI in these challenging infections.
Methods: We systematically queried EMBASE, Cochrane CENTRAL, and PubMed/Medline for studies published until September 15, 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!